BerGenBio

Report Publication Announcement • May 22, 2024

BerGenBio ASA: Invitation to first quarter 2024 results webcast

BerGenBio ASA: Invitation to first quarter 2024 results webcast

Bergen, Norway, 22 May 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL inhibitors for severe

unmet medical needs, will announce its results for the first quarter 2024 on

Wednesday 29 May 2024.

BerGenBio's senior management team will provide a business update at 10:00 am

CET. The presentation will webcast live. To participate in the webcast please

use this link:

https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/ (https://eur03.

safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi

ngpage%2Fhegnarmedia%2F20240529_1%2F&data=05%7C02%7Crune.skeie%40bergenbio.com%7C

bed6cb5730a54ee68bee08dc5a05a2a9%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7C0%7C638

484227462833434%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBT

iI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=fewP6cA4jB2MQi9DhHGyhlssus4kLRRisCCu

FzDDoVM%3D&reserved=0)

A recording of the webcast will be available at www.bergenbio.com in the

Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) shortly

afterwards.

The first quarter financial report and presentation will also be made available

on the Company's website in the Investors/Financial Reports

section (https://www.bergenbio.com/investors/financial-reports) from 7:00am CET

the same day.

-End-

Contacts

Martin Olin, CEO BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK.

The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to MAR

article 17 and section 5-12 of the Norwegian Securities Trading Act.